The call for projects "Evaluation of the medical and/or economic benefit of digital or artificial intelligence-based medical devices" is a benchmark action in the "Digital Health" acceleration strategy, initially launched as part of the AI & Health Grand Challenge. It aims to provide financial support for projects in the clinical evaluation of their benefits. This evaluation is intended to enable the submission of a dossier for assessment by the HAS, or to support a medico-economic model with a view to purchase by a healthcare establishment.

The 3rd wave of this call for projects enables 9 winners to be rewarded for a total amount of €6.9M. The winning projects are:

• The AUSTRAAL project led by Biosency (Clinical benefit study for the Bora Care remote monitoring device)
• The Cardiadapt project led by Ensweet (Evaluation of the economic Superiority and a medical non-inferiority of the Ensweet Cardio device)
• The CREESTALIVE-2023 project led by Cureety (Evaluation of the benefit of Cureety digital telemonitoring in oncology)
• The DIGIPARK project led by Diampark (Mobile application to combat Parkinson's disease)
• The MOUV2 project led by Hinlab (Copernicus solution for monitoring vital constants)
• The OphtAI-Eval2 project led by Evolucare (Multicenter clinical study aimed at validating the diagnostic performance of OphtAI software to aid diagnosis of ocular pathologies in the general population)
• The OPTIRS project carried by RebrAIn (Clinical evaluation of the effectiveness of RebrAIn algorithms in tremor radiosurgery)
• The PSDM project led by Healabs (Reduction of post-stroke complications via remote monitoring of addictive disorders)
• The SEM EDIT-B project led by Alcediag (Impact of EDIT-B diagnosis for depressive and bipolar patients)

Over the 3 waves, 35 projects were awarded a total of €22M.

A fourth wave of the call for projects is open until April 8, 2024.